TR 14035

Key Product Details

Product Description

TR 14035 is a potent integrin α₄β₇ and α₄β₁ antagonist (IC₅₀ values are 7 and 87 nM, respectively). Inhibits binding of HEK 293 cells to osteopontin forms. Orally bioavailable.

Product Specifications for TR 14035

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for TR 14035

The following data is based on the product molecular weight 474.33.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.11 mL	10.54 mL	21.08 mL
5 mM	0.42 mL	2.11 mL	4.22 mL
10 mM	0.21 mL	1.05 mL	2.11 mL
50 mM	0.04 mL	0.21 mL	0.42 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Jürets Inhibition of cellular adhesion by immunological targeting of osteopontin neoepitopes generated through matrix metalloproteinase and thrombin cleavage. PLoS One 2019 PMID: 26840958
• Sircar Synthesis and SAR of N-benzoyl-L-biphenylalanine derivatives: discovery of TR-14035, a dual α₄β₇/α₄β₁ integrin antagonist. Bioorg.Med.Chem. 2002 PMID: 11937364

Product Documents for TR 14035